“KCAS is offering a rapid turnaround time of two to three days for testing and analyses. We also offer our clients the flexibility to design their own selection of biomarkers. Clients can choose a single analyte up to 30 analytes.”
Kansas City, KS (PRWEB) November 17, 2016
KCAS Bioanalytical and Biomarker Services, a leading functional service contract research organization (CRO) has Qualified Meso Scale Discovery’s V-PLEX Human Cytokine 30-plex assay.
The V-PLEX Human Cytokine 30-plex panel consists of 3 autonomous 10-plex panels, Chemokine Panel (human), Cytokine Panel (human) and Proinflammatory Panel (human). These panels are designed to detect secreted biomarkers in a variety of tissues and body fluids. The biomarkers being detected are associated with numerous disorders including Alzheimer’s disease, cancer, depression, and diabetes. “The 30-plex assay covers a plethora of soluble molecules. As individual 10 plexes, it covers 3 specific subsets, offering valuable information to our clients as subsets or as a whole. It is the quickest, most cost-effective method we can qualify and reliably reproduce.” States Joyce Slusser Ph.D., Senior Scientist.
“KCAS is offering a rapid turnaround time of two to three days for testing and analyses. We also offer our clients the flexibility to design their own selection of biomarkers. Clients can choose a single analyte up to 30 analytes.” States Dominic Warrino Ph.D. Technical Advisor for KCAS’ Biologics Department.
Earlier this year, KCAS conducted a study with Cryoport evaluating the impact of transportation of samples by cold chain logistics compared to standard liquid nitrogen and dry ice on stability of all the 30 analytes. KCAS is the only laboratory to evaluate the impact of temperature and transport packaging at deep frozen temperatures on these 30 critical biomarkers.
KCAS Bioanalytical & Biomarker Services is a contract laboratory with 37+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure of 14 years at the company to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under fit-for-purpose Non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies. Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 16 FDA inspections. Learn more at: http://www.kcasbio.com